Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Rhea-AI Summary
Tiziana Life Sciences (Nasdaq: TLSA) reported that Executive Chairman and founder Gabriele Cerrone, via Panetta Partners, purchased 15,000 common shares at $1.11 per share. This transaction increased his total holding to 44,772,230 shares, representing 34.89% of Tiziana's issued share capital.
Positive
- Executive chairman buys 15,000 TLSA shares at $1.11 each
- Gabriele Cerrone’s stake increases to 44,772,230 shares
- Executive chairman now holds 34.89% of issued share capital
Negative
- None.
News Market Reaction – TLSA
In the Jun 15 session, TLSA gained 0.91%, reflecting a mild positive market reaction. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Conference participation | Neutral | -0.7% | Announcement of corporate presentation at Jefferies Global Healthcare Conference. |
| May 21 | Trial enrollment update | Positive | -9.3% | Full enrollment of 48 patients in INFORM-MS Phase 2a MS trial. |
| May 19 | Clinical data update | Positive | +4.0% | Updated EAP data showing tolerance and fatigue improvement trends in 14 MS patients. |
| May 14 | Imaging data readout | Positive | -3.3% | Initial Phase 2 PET imaging data in MSA showing reduced neuroinflammatory activity. |
| Apr 16 | Preclinical data | Positive | +0.8% | Positive Long COVID mouse data linking intranasal anti-CD3 to improved cognition. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and corporate updates have sometimes been followed by negative price reactions, indicating a tendency for the stock to sell off on good news.
Over recent months, Tiziana has focused on intranasal foralumab across multiple neuroinflammatory indications, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, aging-related neuroinflammation, and Long COVID. Several updates, such as full enrollment of the INFORM-MS Phase 2a trial and positive imaging or preclinical data, were followed by mixed price reactions, with both gains and notable declines. The current insider purchase by the Executive Chairman adds a governance and confidence signal on top of an ongoing, data-driven clinical narrative and a company that reported a net loss of $18.4 million in 2025.
Key Terms
immunomodulation medical
anti-cd3 medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 15,000 common shares at
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
